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Pancreatic and duodenal homeobox 1 (PDX1), a
member of the homeodomain-containing transcrip-
tion factor family, is a key transcription factor impor-
tant for both pancreas development and mature b
cell function. The ectopic overexpression of Pdx1,
Neurog3, and MafA in mice reprograms acinar cells
to insulin-producing cells. We developed a quantita-
tive PCR-based gene expression assay to screen
more than 60,000 compounds for expression of
each of these genes in the human PANC-1 ductal
carcinoma cell line. We identified BRD7552, which
upregulated PDX1 expression in both primary human
islets and ductal cells, and induced epigenetic
changes in the PDX1 promoter consistent with
transcriptional activation. Prolonged compound
treatment induced both insulin mRNA and protein
and also enhanced insulin expression induced by
the three-gene combination. These results provide
a proof of principle for identifying small molecules
that induce expression of transcription factors to
control cellular reprogramming.
INTRODUCTION
Pancreatic and duodenal homeobox 1 (PDX1) is a key tran-
scription factor involved in pancreas development and b cell
function (Babu et al., 2007; McKinnon and Docherty, 2001).
Homozygous disruption of Pdx1 in mice and PDX1 in human
patients causes pancreatic agenesis. Heterozygous mutation
is associated with both type 2 diabetes and maturity onset dia-
betes of the young, type 4 (Ahlgren et al., 1997; Oliver-Krasinski
et al., 2009; Stoffers et al., 1997). In the adult pancreas, PDX1 is
expressed in b cells and d cells and controls the expression
of key b cell markers such as insulin, glucose transporter 2,
MafA, glucokinase, and islet amyloid polypeptide (Babu et al.,
2007; McKinnon and Docherty, 2001). Furthermore, ectopic
overexpression of PDX1 is essential for b cell neogenesis, both
through direct differentiation from pluripotent or progenitorChemistry & Biology 20, 1513–152cells and through transdifferentiation from mature non-b cells
such as liver, acinar, and ductal cells (Akinci et al., 2012; Ferber
et al., 2000; Kaneto et al., 2005; Karnieli et al., 2007; Kojima et al.,
2002; Kubo et al., 2011; Motoyama et al., 2009; Wu et al., 2007;
Yamada et al., 2001; Yang et al., 2002). A notable recent
success in the transdifferentiation field was the generation of
functional insulin-producing b cells from acinar cells in mice
after viral transduction of the pancreas with Pdx1, Neurog3,
and MafA (Zhou et al., 2008). These results were repeated in
cell culture using the rat exocrine cell line AR42J (Akinci et al.,
2012), suggesting that in vitro cell models can enable the study
of cellular reprogramming.
From a therapeutic perspective, viral introduction of exoge-
nous genetic material raises concerns regarding genomic inte-
gration and tumorigenicity (Barrilleaux and Knoepfler, 2011).
An attractive alternative is to use small molecules that achieve
temporal high expression of transcription factors. Recent
efforts to this end have focused on the factors required for the
generation of induced pluripotent stem (iPS) cells (Takahashi
and Yamanaka, 2006). This approach identified kenpaullone
as a potential replacement for Klf4 (Lyssiotis et al., 2009),
a transforming growth factor b receptor inhibitor as a potential
replacement for Sox2 and c-Myc (Ichida et al., 2009), and Src
inhibitors as other replacements for Sox2 (Staerk et al., 2011).
These results suggest that novel screening methods can
identify compounds that aid in the reprogramming process.
Herein we report the development of a gene expression-based
assay to perform high-throughput screening of 60,752 com-
pounds for endogenous expression of PDX1, NEUROG3, or
MAFA. We identified BRD7552, a compound that increased
PDX1 mRNA levels in a dose- and time-dependent manner in
human PANC-1 cells, primary human islets, and human duct-
derived cells (HDDCs). BRD7552 modified histone H3 tail modi-
fications associated with transcriptional activation, suggesting
that the compound may induce PDX1 expression through
either direct or indirect epigenetic control. Further mechanism
of action studies suggest a role for the transcription factor
FOXA2 in BRD7552-induced PDX1 transcriptional activation.
BRD7552 can partially replace PDX1 in the genetic induction of
insulin expression in PANC-1 cells. These results lay a founda-
tion for the development of novel small molecules as useful
tools with which to manipulate the endogenous expression of
master regulatory transcription factors.2, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1513
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Transcription Factor Target Validation in PANC-1 Cells
In order to develop an in vitro model for high-throughput chem-
ical screening, we assessed the suitability of human PANC-1
ductal adenocarcinoma cells. Although not an acinar cell line,
PANC-1 cells are amenable to high-throughput screening and
provide a good framework for b cell neogenesis. After cotrans-
fection of full-length PDX1, NEUROG3, andMAFA and antibiotic
selection over 2 weeks, we observed an increase in C-peptide
immunofluorescence in a majority of cells (Figure 1A). Each
transcription factor was highly expressed in these cells (Figures
1B–1D). Interestingly, at the end of 2 weeks, the localization of
each transcription factor was both nuclear and cytoplasmic,
suggesting that protein export from the expected nuclear
location may occur during this time. Cytokeratin-19 (CK19), a
ductal marker highly expressed in PANC-1 cells, was signifi-
cantly downregulated in these cells, consistent with reports of
its negative regulation by PDX1 (Deramaudt et al., 2006) (Fig-
ure 1E). Quantitative PCR (qPCR) revealed that each of the
three transcription factors was highly upregulated 3 days after
transfection but decreased to lower levels after 2 weeks in
culture (Figure 1F). Insulin mRNA levels were induced greater
than 1,000-fold in transfected cells, albeit from an undetectable
basal state. On the other hand, hormones expressed in other
pancreatic endocrine cell types, such as glucagon, somato-
statin, and pancreatic polypeptide, were induced less than
10-fold (Figure 1F). Examination of the threshold cycle (Ct)
values of control PANC-1 cells, as well as the DCt values relative
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
reveals that, with the exception of PDX1 (Ct 28.0), these hor-
mones and transcription factors are more or less not expressed
in PANC-1 cells. However, the 1,000-fold increase in PDX1,
NEUROG3, andMAFA, as well as the 2-week 1,000-fold upregu-
lation of INS, would put these Ct values nearer to those of
GAPDH. These results suggest that an initial burst of expression
of PDX1, NEUROG3, and MAFA may be sufficient to induce
insulin expression in PANC-1 cells.
Despite the fact that these cells demonstrated some signs
of reprogramming, the process appeared to be incomplete.
Insulin levels were not comparable to normal b cells, and neither
basal insulin secretion nor glucose-stimulated insulin secretion
was detected (data not shown). Furthermore, transfected cells
started dying after 3 weeks in culture, which is consistent with
results described in AR42J cells (Akinci et al., 2012). The pro-
liferation marker Ki67 was reduced to a great extent after
transfection and selection (Figure 1G), and total cell number
was reduced by about 45% compared to cells transfected
with a control vector (Figure 1H). Anchorage-independent cell
growth and cell invasion, general properties of human cancer
cells, were reduced by about 25% by transcription factor
overexpression (Figure 1I and Figure S1 available online). These
data suggest that overexpression of PDX1, NEUROG3, and
MAFA suppresses cell proliferation and may adopt some
endocrine cell-like features.
Screening for Induction of PDX1 Expression
Given the induction of insulin expression in PANC-1 cells under
these conditions, we used this model system to identify small1514 Chemistry & Biology 20, 1513–1522, December 19, 2013 ª2013molecules that induce the endogenous expression of PDX1.
We therefore developed a gene expression-based assay using
real-time qPCR (Arany et al., 2008) to identify potential small-
molecule inducers. Using transfection of all three genes as a
positive control, we observed that assay Z0-factor values, a
measure of statistical effect size and assay quality (Zhang
et al., 1999), were greater than 0.5 for each of the three genes
(Figure 2A), indicating that the assays were suitable for high-
throughput screening.
We then screened 60,752 compounds to identify inducers of
transcription factor expression in PANC-1 cells after 3-day
treatment (Figures S2A and S2B). The screening collection
included compounds from libraries prepared by diversity-
oriented synthesis (DOS) (Schreiber, 2009), as well as kinase-
biased, chromatin-biased, commercial compound, bioactive,
and natural product libraries. Although no hits were identified
in the NEUROG3 or MAFA screens, we identified BRD7552,
a glucose-derived DOS compound, as a hit in the PDX1
screen (Figures 2B and S2C). BRD7552 increased PDX1
mRNA levels two- to fourfold, with a maximal effect at 5 mM
(Figure 2C). The expression of MAFA was only marginally
increased by BRD7552, but no NEUROG3 induction was de-
tected (Figures S2D and S2E).
Five- and nine-day treatment of cells with BRD7552 further
increased PDX1 expression (Figure 2C), but effects were
observed as early as six hours after compound treatment
and gradually increased over time (Figure 2D). After 3-day
compound washout, the expression level of PDX1 returned
to original levels (Figure S3A), suggesting that the effects
of BRD7552 are reversible. Immunofluorescence revealed
PDX1 to be cytoplasmic (Figure S3B), perhaps reflecting an
immature or stressed state (Guo et al., 2013; Kawamori
et al., 2003; Macfarlane et al., 1999). We then assessed the
effects of BRD7552 on endocrine cells. We observed an
increase in PDX1 expression in mouse aTC cells (Figure S3C),
which express levels of PDX1 similar to those of PANC-1
cells. However, mouse bTC cells, which already have high
levels of PDX1 expression, showed no further induction (Fig-
ure S3D), suggesting that BRD7552 may impinge on a pro-
cess already active in b cells. In accordance with the qPCR
results, BRD7552 induced a dose-dependent increase in
PDX1 protein levels after BRD7552 treatment in PANC-1 cells
(Figures 2E, 2F). Protein levels of CK19, a ductal marker
negatively regulated by PDX1, were modestly decreased by
compound treatment as well (Figures 2E). We confirmed that
the relatively high concentrations of BRD7552 used had no
effect on PANC-1 apoptosis (Figures S3E and S3F). Because
PANC-1 cells express some PDX1 under basal conditions,
these data suggest that even a moderate induction may be
sufficient to promote the downstream effects of this tran-
scription factor.
BRD7552 Increases Insulin Expression
Next, we sought to determine whether BRD7552 has an
effect on insulin levels. Nine-day treatment of PANC-1 cells
with BRD7552 caused a dose-dependent increase in insulin
mRNA expression (Figure 3A). We also tested the effects of
BRD7552 in primary human islets using a cell culture system
developed for high-throughput screening (Walpita et al.,Elsevier Ltd All rights reserved
Figure 1. Three Transcription Factors Induce b Cell-like Characteristics in Human PANC-1 Cells
Immunofluorescence analysis of control and triply overexpressed (TOE) PANC-1 cells after 2 weeks in cell culture.
(A) C-peptide.
(B) NEUROG3.
(C) PDX1.
(D) MAFA.
(E) Cytokeratin-19 (CK19). Nuclei were stained with Hoechst 33342 dye. Scale bars, 100 mm.
(F) qPCR analysis of insulin,MAFA,NEUROG3,PDX1,PAX4,GCG,SST, andPPY gene expression in TOE cells after 3-day and 2-week cultures. Gene expression
was normalized by GAPDH expression and scored relative to control vector-transfected cells. Ct (Ctrl) indicates basal threshold cycle (Ct) value of each gene in
DMSO-treated PANC-1 cells. DCt refers to the GAPDH-normalized levels of expression of these genes in control PANC-1 cells. Data represent the mean ± SD of
three independent experiments.
(G) Immunofluorescence analysis of Ki67 (green) performed on TOE cells 2 weeks after transfection and selection. Nuclei were stained with Hoechst 33342 dye.
(H) Total nuclei of TOE cells in each well were detected by Hoechst fluorescence and counted by automated microscopy. Data represent the mean and standard
error of eight independent replicates. *p < 0.0001 (t test).
(I) Quantification of PANC-1 colony formation in soft agar by nucleic acid detection. RFU, relative fluorescence units. *p < 0.01 (t test).
See also Figure S1 and Table S1.
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significant dose-dependent induction of PDX1 (Figure 3B) after
3 or 5 days and of insulin (Figure 3C) after a 5-day treatment. It
is important to note that, because of the heterozygous natureChemistry & Biology 20, 1513–152of this primary culture system, we could not determine which
cell types were responsible for the increase in gene expres-
sion; however, we observed no changes in cell numbers
upon 3-day treatment with BRD7552 (Figure S4B), suggesting2, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1515
Figure 2. BRD7552 Induces PDX1 Gene and
Protein Expression
(A) Assay development of gene expression in 384-
well plates. Triply overexpressed (TOE) cells were
compared to DMSO-treated PANC-1 cells for
expression of indicated genes. Z0 factors for each
assay are listed below each gene name.
(B) Chemical structure of BRD7552.
(C) qPCR analysis of PDX1 expression in PANC-1
cells following 3-, 5-, and 9-day treatment with
the indicated concentrations of BRD7552. DCt
(DMSO) is the relative expression level of the
target genes compared to the control gene,
GAPDH, as an indication of the basal levels of
expression in PANC-1 cells. The fold change was
scored relative to control cells treated with DMSO.
Data represent the mean ± SD of three indepen-
dent experiments.
(D) qPCR analysis of PDX1 expression induced
by 5 mM BRD7552 at the indicated time points.
*p < 0.001 (t test).
(E) Assessment of protein levels of PDX1 and
cytokeratin-19 (CK19) in PANC-1 cells treated
with the indicated concentrations of BRD7552 for
5 days. Actin was used as an internal loading
control.
(F) Quantification of PDX1 protein levels induced
by 3-day BRD7552 treatment as measured by
ELISA. Data represent the mean ± SD of three
independent experiments.
See also Figures S2 and S3 and Table S1.
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have explained these results. In order to more faithfully mimic
our screening conditions, we tested the effects of BRD7552 in
HDDCs, which were derived in vitro directly from purified
CA19-9+ ductal cells through epithelial-mesenchymal transition
and had been shown to be capable of differentiation toward
b-like cells both in vitro and in vivo (Lysy et al., 2012). After
3-day treatment, BRD7552 induced PDX1 expression in two
donor samples in a dose-dependent manner, and in a third
donor sample at the lowest concentration (Figure 3D), indi-
cating that this compound retains activity in primary human
pancreatic cells.
BRD7552 Changes the Epigenetic Status
of the PDX1 Promoter
In order to investigate whether BRD7552 upregulates PDX1
expression by modifying its promoter region, we performed
bisulfite sequencing and chromatin immunoprecipitation
(ChIP) qPCR to assess DNA methylation levels and histone
modifications in BRD7552-treated PANC-1 cells (Figure 4A).
Histone H3 acetylation and trimethylation at lysine 4
(H3K4me3) are enriched in active promoter regions (Barski
et al., 2007; Eberharter and Becker, 2002; Koch et al., 2007),
whereas that at lysine 9 (H3K9me3) and lysine 27 (H3K27me3)
are associated with transcriptional repression (Barski et al.,
2007; Koch et al., 2007). BRD7552 increased H3 acetyla-
tion (Figure 4B) and H3K4me3 (Figure 4C) and decreased1516 Chemistry & Biology 20, 1513–1522, December 19, 2013 ª2013H3K9me3 (Figure 4D), results that are consistent with transcrip-
tional activation of PDX1. H3K27 methylation was unaffected
by compound treatment (Figure 4E). We also observed similar
changes in a portion of the insulin promoter (Figure S5). The
proximal promoter of PDX1 in PANC-1 cells was hypomethy-
lated, and no significant change in DNA methylation status
was observed upon compound treatment (Figure S6). We
measured cellwide changes in histone modification in PANC-1
cells and observed that BRD7552 increases total H3K9 and
H3K27 trimethylation levels (Figure S7). Remarkably, these
changes are in the opposite direction from the effects on the
PDX1 and insulin promoters, suggesting that the latter effects
are not due to generic cellular effects on chromatin status.
These results suggest that BRD7552 acts at the chromatin level
to induce PDX1 expression in PANC-1 cells.
FOXA2 Is Involved in BRD7552 Activity
In order to further understand the mechanism of action of
BRD7552, we performed gene expression profiling in PANC-1
cells treated with DMSO or BRD7552. Genes involved in
insulin production were not increased; however, gene set
enrichment analysis (GSEA) (Subramanian et al., 2005) revealed
that genes downregulated by the forkhead box transcription
factor FOXA2 were positively enriched in control cells (Fig-
ure 5A), suggesting that BRD7552 increases either expression
or activity of FOXA2. Accordingly, knockdown of FOXA2
(Figure S8) abolished PDX1 induction by BRD7552 (Figure 5B),Elsevier Ltd All rights reserved
Figure 3. BRD7552 Induces Insulin Expression in PANC-1 Cells
(A) qPCR analysis of insulin expression on PANC-1 cells following 3-, 5- and 9-
day treatment with the indicated concentrations of BRD7552. Gene expres-
sion was normalized by GAPDH and actin expression and was scored relative
to the control cells treated with DMSO. Data represent the mean ± SD of three
independent experiments.
(B and C) qPCR analysis of PDX1 (B) and insulin (INS) expression (C) in
dissociated human islet cells from donor 3 (Figure S3), which were treated with
the indicated concentrations BRD7552 for 3 or 5 days. Gene expression was
normalized by GAPDH and actin expression and was scored relative to the
control vector-transfected cells. Data represent the mean ± SD of three in-
dependent experiments.
(D) qPCR analysis of PDX1 expression in HDDCs at passage 3 or 4 after in-
cubation with BRD7552 at the indicated concentrations for 3 days. Gene
expression was normalized by TBP expression and scored as the fold change
relative to 0.1% DMSO-treated cells. P, passage.
See also Figure S4 and Table S1.
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These results suggest that BRD7552 acts in a FOXA2-depen-
dent manner to increase PDX1 expression in human ductal
cells.
Most Structural Features of BRD7552 Are Required for
Activity
We assessed the structure-activity relationship of BRD7552
based on a collection of 102 analogues present within the
screening collection, as well as on newly synthesized analogues.
BRD0749, the stereoisomer of BRD7552, had very weak effects
on PDX1 expression after 5-day treatment (Figure 6), suggesting
that the R configuration of C2 is crucial for this activity. We next
explored the carbamate substituent at C4; its removal resulted
in a complete loss of activity (YW2), whereas other ester
analogues (YW5 and YW6) had effects similar to those of
BRD7552 (Figure 6). YW3 and YW4, however, the synthetic
intermediates of YW5 and YW6, were not active, suggesting
that the primary hydroxyl group at C6 was essential. Further
exploration of the C4 carbamate substituent revealed that
many small changes resulted in a loss of activity (Figure 6).
Thus, there appears to be little flexibility in the structural
requirements for BRD7552 activity.Chemistry & Biology 20, 1513–152BRD7552 Partially Complements PDX1 in PANC-1 Cells
To test whether BRD7552 could truly replace PDX1, we treated
cells with 5 mM BRD7552 and the combination of MAFA and
NEUROG3, or all three transcription factors. Because the
induction effect of BRD7552 was reversible (Figure S2A), the
compound was administrated every 3 days. After 2-week
culture and antibiotic selection, the combination of plasmids
and BRD7552 resulted in higher insulin mRNA expression
levels compared to plasmids alone (Figure 7A). Immunofluores-
cence analysis revealed that all three genes were still required
to detect C-peptide expression, but that the addition of
BRD7552 increased those levels further (Figure 7B). These
data demonstrate that PDX1 can be partially replaced by
BRD7552.
DISCUSSION
The identification of chemical inducers of master transcription
factors has become an attractive strategy to perturb and study
biological systems. We developed a qPCR-based assay for
high-throughput detection of PDX1 expression and used this
assay to screen over 60,000 compounds in human PANC-1
cells. One compound, BRD7552, reproducibly increased
PDX1 expression in a dose- and time-dependent manner and
induced insulin expression after longer treatment times.
Changes in chromatin modification status in the PDX1 and in-
sulin promoters are consistent with the transcriptional changes
in these genes. To evaluate the mechanism of action of
BRD7552, we performed gene expression profiling and
GSEA, which revealed that genes downregulated by the
transcription factor FOXA2 were also downregulated by
BRD7552. Knockdown of FOXA2 abolished BRD7552 effects
on PDX1 expression. Interestingly, FOXA2 was recently found
to occupy the PDX1 promoter at several domains and to be
especially important during development (Gao et al., 2008).
Further studies are required to deconvolute the mechanism
and identify the primary target of BRD7552, as well as to deter-
mine the requirements for inducing a fully glucose-responsive
b cell state.
We observed an increase in insulin and PDX1 expression
in human islets and HDDCs after compound treatment.
BRD7552 serves as a partial chemical complement for PDX1,
increasing insulin expression in the presence of NEUROG3
and MAFA overexpression. Further studies designed to
determine the precise intracellular target of BRD7552 will
enable identification of additional targets for screening to
induce more potent increases in PDX1 expression. With regard
to cancer, it is noteworthy that, by targeting a master regulatory
transcription factor for upregulation by a small molecule, we
have pushed a cancer cell line into a nonproliferative state.
It remains to be seen whether this transdifferentiation
strategy is feasible for developing novel approaches to target-
ing cancer cells.
Transcription factors have long been considered ‘‘undrug-
gable’’ targets for therapeutic development (Dandapani and
Marcaurelle, 2010; Payne et al., 2007). More conven-
tional targets for high-throughput screening have included
G protein-coupled receptors and enzyme classes such as
kinases and histone deacetylases (HDACs). These results2, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1517
Figure 4. Chromatin Modifications Induced
by BRD7552 at the PDX1 Promoter Are
Consistent with Transcriptional Activation
(A) Location of the primer pairs used for ChIP-
qPCR for the human PDX1 gene. PANC-1 cells
were treated with DMSO (light gray bars) and 5 mM
BRD7552 (dark gray bars) for 3 days.
(B–E) The following modifications were analyzed
by ChIP-qPCR: acetylated H3 (B), H3K4me3 (C),
H3K9me3 (D), and H3K27me3 (E).
Data represent the mean ± SDs of four indepen-
dent qPCR experiments. *p < 0.05.
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tion factor expression can be identified by high-throughput
screening. The extremely low hit rate in our assay might indi-
cate that transcription factor expression is only rarely targeted
by current screening collections (Burke and Schreiber, 2004;
Schreiber, 2009). In fact, the only hit we identified was a
member of a library of compounds prepared by DOS. Such
compounds have novel structures not well represented in
other common screening collections (Clemons et al., 2011).
Identification of the structural features critical for effects on
transcription factors, coupled with screening collections
that fill the gaps in chemical diversity space, will be useful for1518 Chemistry & Biology 20, 1513–1522, December 19, 2013 ª2013 Elsevier Ltd All rights renovel high-throughput screening aimed
at less conventional targets.
Other small-molecule modulators of
epigenetic regulation, such as the DNA
methyltransferase inhibitor 50-azadeoxy-
cytidine, increase NEUROG3 expression
in PANC-1 cells (Lefebvre et al., 2010).
Additionally, HDAC inhibitors amplify
endocrine progenitors during develop-
ment in mice (Haumaitre et al., 2008).
Nevertheless, cellular toxicity of general
HDAC inhibitors has prevented their
application in differentiation, transdif-
ferentiation, and other related studies.
This study provides a path throughwhich to identify small-molecule tools to manipulate the ex-
pression of master regulatory transcription factors. BRD7552,
a small molecule with a distinct chemical structure, can
induce PDX1 expression and demonstrates the potential
to enhance a b cell-like phenotype in a human pancreatic
ductal cell line in vitro. Such a compound may have particular
utility in improving the efficiency of pancreatic differentiation
from human iPS cells. Remaining challenges include fully
uncovering the compound’s mechanism of action, further
increasing levels of PDX1 and insulin expression, and improving
potency and pharmacokinetic properties through medicinal
chemistry.Figure 5. FOXA2-Targeted Gene Set Is
Linked to BRD7552 Treatment in PANC-1
Cells by Gene Set Enrichment Analysis
(A) GSEA enrichment plot showing expression
enrichment of a set of FOXA2-downregulated
genes. Bars represent individual genes in a
ranked data set list. Expression of the majority of
these genes was enriched in the DMSO-treated
PANC-1 cells compared to BRD7552-treated
cells. Heat map of the 27 genes in the leading
edge of the gene set.
(B) qPCR analysis of PDX1 expression induced
by 5 mM BRD7552 and FOXA2 knockdown in
PANC-1 cells. Data represent the mean ± SD.
*p < 0.001 (t test).
See also Figure S8 and Table S1.
served
Figure 6. Most Structural Features of BRD7552 Are Required for Activity
The common chemical structure of all analogues is shown at the top. Alterations of the stereochemistry at the C2 position, as well as the identities of R (red)
and R0 (blue) groups, are indicated below. PDX1 induction of each small molecule was tested at 10 mM after 3- and 5-day treatments. The fold change was
normalized by GAPDH expression and scored relative to DMSO-treated control cells. Data represent the mean of two independent experiments.
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The ability to induce cellular reprogramming in an on-
demand fashion with small molecules has the potential
to transform cell biology and discovery of therapeutics.
In particular, the ability to replenish b cell mass by repro-
gramming other cells in the pancreas would represent
a significant advance toward novel diabetes therapies. In
this study, we aimed to identify small molecules capable of
inducing the expression of the transcription factors PDX1,
NEUROG3, or MAFA, all of which are master regulatory
genes involved in b cell development. First, we observed
that transfection of a human ductal cancer cell line withChemistry & Biology 20, 1513–152these transcription factors, followed by prolonged culture,
induces phenotypic changes toward a b cell-like state. We
then performed chemical screening to identify compounds
capable of replacing these factors. High-throughput
screening using qPCR as a readout has made possible the
rapid identification of novel compounds to induce target
gene expression. We identified BRD7552, a compound that
induces PDX1 expression in PANC-1 cells in a dose-depen-
dent manner. The epigenetic changes induced by BRD7552
are consistent with transcriptional activation, and
BRD7552 acts in a FOXA2-dependent manner. Prolonged
treatment with BRD7552 also induces expression of insulin,
and this compound is active in primary human islet cells2, December 19, 2013 ª2013 Elsevier Ltd All rights reserved 1519
Figure 7. BRD7552 Can Partially Comple-
ment PDX1 in PANC-1 Cells
(A) qPCR analysis of insulin expression of trans-
fected PANC-1 cells in the presence or absence of
5 mM BRD7552 after 2 weeks in culture. Gene
expression was normalized by GAPDH and actin
expression and was scored relative to the control
vector-transfected cells. Data represent the
mean ± SD of three independent experiments.
(B) Immunofluorescence analysis of C-peptide
expression (red) in transfected PANC-1 cells in
the absence or presence of 5 mM BRD7552 after
2 weeks in culture. Nuclei were stained blue with
Hoechst 33342 dye. Scale bars, 100 mm.
See also Table S1.
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the eventual development of a toolkit of small-molecule
replacements for reprogramming factors.EXPERIMENTAL PROCEDURES
Cell Cultures and Compounds
PANC-1, aTC cells, and bTC cells (American Type Culture Collection) were
cultured in DMEM containing 10% fetal bovine serum (FBS) and 100 U ml1
penicillin/streptomycin (P/S). Human islets were obtained from the Integrated
Islet Distribution Program and were cultured as described previously (Walpita
et al., 2012). Donor information is provided in Figure S4. HDDCs were
expanded from cultures of CA19-9+ human ductal cells purified from
islet-depleted pancreatic tissues using immunomagnetic bead separation as
previously described (Yatoh et al., 2007). Human cadaveric donor cells were
obtained from the University of Chicago. In brief, freshly isolated CA19-9+
ductal cells were initially seeded onto tissue culture-treated dishes in CMRL
medium (Gibco) containing 10% FBS and 1% P/S (Cellgro). After 72–96 hr,
the medium was changed for EGM-2 MV BulletKit medium (Lonza) without
hydrocortisone to stimulate proliferation of HDDCs. The medium change
was then performed twice weekly. Proliferating cells were passaged at
80% confluence using 0.25% trypsin (Cellgro) and subcultured at 5,000
cells/cm2. Cells were cultured at 37C in a humidified atmosphere containing
5% CO2. For differentiation assays, HDDCs were plated at 2 3 10
4 cells/cm2
on uncoated, tissue culture-treated, 12-well dishes in DMEM/F-12 containing
0.1% FBS. The compounds BRD7552, BRD0749, BRD8583, BRD3185,
BRD6666, BRD7781, BRD5843, BRD7929, BRD5733, YW5, YW6, YW3,
YW4, YW2, and CZ1 were synthesized in our laboratory. The synthetic route
and chemical characterization of BRD7552 are included as Supplemental
Information.
RNA Isolation and Real-Time PCR
Total RNA was extracted from cells using the RNeasy Plus Mini Kit (QIAGEN).
Reverse transcription was performed using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) with RNase inhibitor (QIAGEN)
according to the manufacturer’s protocol. Real-time qPCR reactions were
performed with SYBR Green PCR Master Mix in 384-well format using a
7900HT plate reader (Applied Biosystems). cDNA primers for FOXA2
(QT00212786) and FOXO1 (QT00044247) were purchased from QIAGEN.
Other cDNA primers were obtained from Eurofins MWG Operon, the se-
quences of which are listed in Table S1.
Plasmid Transfection and siRNA Knockdown
Human PDX1 (RC222354), NEUROG3 (RC224767), MAFA (RC214782) and
control vector (PS100001) were obtained from Origene. Both 1 mg/ml of
each plasmid and 3 mg/ml of control plasmid were transfected into PANC-1
cells using Lipofectamine 2000 (Invitrogen), and cells were selected with
neomycin (Sigma Aldrich). siRNAs against FOXA2 (GS3170) and FOXO1
(GS2308) were purchased from QIAGEN. siRNA against FOXA2, FOXO1,1520 Chemistry & Biology 20, 1513–1522, December 19, 2013 ª2013and scramble siRNA were transfected with lipofectamine RNAiMAX reagent
(Invitrogen) at a final concentration of 100 nM.
High-Throughput Screening
PANC-1 cells were plated and allowed to attach overnight before the com-
pound pin-transferred from concentrated DMSO stocks at a final concentra-
tion of 20 mM. Cells were treated with the compound for 3 days before the
qPCR assay. The Cells-to-CT Kit (Ambion) was used for cell lysate and reverse
transcription. A qPCR assay was performed using the Twister II Microplate
Handler (Caliper Life Sciences) and the LightCycler 480 System (Roche
Applied Science). The data were uploaded and analyzed using Genedata
software. Approximately 300 compounds scoring greater than two standard
deviations from the DMSO distribution were selected for retesting. To confirm
screening positives, dose-response curves were generated using GAPDH
as a control. Compound purity and identity were determined by ultraperform-
ance liquid chromatography mass spectrometry (Waters). A detailed protocol
for the high-throughput qPCR assay is provided in the Supplemental Experi-
mental Procedures.
Western Blot Analysis
Cells were lysed on ice in radioimmunoprecipitation assay buffer (20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2 EDTA, 1 mM EGTA, 1% Nonidet
P-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate, 1 mM Na3VO4, 1 mg ml
1 leupeptin, protease inhibitors,
and phosphatase inhibitors). Total protein was separated by 4%–12% SDS-
PAGE and transferred to a polyvinylidene fluoride membrane. Blots were
developed using SuperSignal Chemiluminescent Substrate (Thermo Fisher).
Images were quantified using ImageJ software (National Institutes of Health).
Antibodies used for western blotting were goat anti-PDX1 antibody from
Abcam (1:500), mouse anti-CK19 antibody from Sigma-Aldrich (1:500), and
mouse anti-b-actin antibody from Sigma-Aldrich (1:5,000).
ELISA
The Human PDX1 ELISA Kit (Cusabio) was used to quantitatively determine
PDX1 concentrations in cell lysates. Briefly, 100 ml of standards or samples
were added into a 96-well and incubated for 2 hr at 37C. Liquid from each
well was removed, and wells were incubated for 1 hr with biotinylated anti-
body, washed 3 times, and incubated with horseradish peroxidase-avidin.
3,30,5,50-Tetramethylbenzidine substrate was added to each well and
incubated for 15–30 min at 37C, followed by stop solution. The optical
density of each well was determined within 5 min using a microplate reader
set to 450 nm.
Immunofluorescence and Microscopy
Cells were seeded into black optical 96-well plates overnight for attachment,
followed by compound treatment. Cells were fixed for 20 min in 4% parafor-
maldehyde, permeabilized for 20 min with 0.1% Triton X-100, blocked with
PBS containing 2% BSA at 4C overnight, and incubated at 4C overnight
with the following primary antibodies: mouse (Ms) C-peptide (Chemicon
International), goat Pdx1 (Abcam), rat brain (Rb) neurogenin 3 (EMDMillipore),Elsevier Ltd All rights reserved
Chemistry & Biology
Small Molecule-Induced PDX1 ExpressionRb Mafa (Abcam), Ms CK19 (Sigma-Aldrich), and Ms Ki-67 (Abcam) at 1:100
dilution. Cyanine 3 (Cy3)-labeled or Cy2-labeled secondary antibodies
(Jackson ImmunoResearch) were added, along with Hoechst 33342 dye
(Invitrogen), and observed with an Axiovert 200M fluorescence microscope
(Zeiss) at 3400 magnification. Cell number analysis was performed with an
ImageXpress Micro automated microscope (Molecular Devices) using a 43
lens objective with laser-based focusing. Nuclear staining was handled in
Photoshop (Adobe Systems) to improve visibility. Each image in Figure 1
was handled in the same way (brightness level 75, with blue hues reduced
to 24).
Anchorage-Independent Colony Formation Assay
PANC-1 cells were trypsinized and tested for soft agar colony formation
using a CytoSelect 96-Well Cell Transformation Assay (Cell Biolabs) with
CyQUANT GR Dye (Molecular Probes) to measure total cellular nucleic
acid levels. Fluorescence was detected with an Analyst HT plate reader
(LJL BioSystems) using a 485/520 nm filter set.
ChIP-qPCR Assay for Histone Tail Modifications
PANC-1 cells were treated with DMSO or 5 mM BRD7552 for 3 days in 15-cm
tissue culture dishes. ChIP was performed using the Magna ChIP G Kit
(EMDMillipore) according to the manufacturer’s protocol. The sonication pro-
tocol (163 10 s on with a 2-min refractory period, duty cycle 10, and output 5)
was optimized for the Branson Sonifier 250. ChIP was performed for acety-
lated histone H3 (Rb anti-acetyl histone H3; EMD Millipore), H3K4me3
(Ms anti-histone H3 trimethyl K4; Abcam), H3K9me3 (Rb anti-histone H3
trimethyl K9; Abcam), and H3K27me3 (Ms anti-histone H3 trimethyl K27;
Abcam). Histone H3 (Rb anti-histone H3; Abcam) was used as the positive
control, and normal rabbit immunoglobulin G (EMD Millipore) was used as
the negative control. qPCR was performed as described before. The primer
sequences used are listed in Table S2.
DNA Methylation Assay
Four enriched CpG islands were selected for analysis (Ma et al., 2010).
PANC-1 cells were treated with DMSO and 5 mM BRD7552 for 9 days. The
cells in frozen medium were sent to SeqWright for bisulfite sequencing.
Microarray and GSEA Analysis
PANC-1 cells were treated with DMSO and 5 mM BRD7552 for 72 hr. mRNA
was extracted from cells using the RNeasy Plus Mini Kit (QIAGEN), and the
GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) was used for
gene expression profiling. GSEA was performed using the GSEA 2.0 software
package (http://www.broad.mit.edu/tools/software.html).SUPPLEMENTAL INFORMATION
Supplemental Information includes Seupplemental Experimental Procedures,
eight figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.10.013.
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